NL-OMON32042已完成4 期
A DOUBLE BLIND, SINGLE DOSE, RANDOMIZED, 4-PERIOD CROSS-OVER, PLACEBO-CONTROLLED CLINICAL STUDY OF FIXED COMBINATION BECLOMETHASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE (CHF 1535) VERSUS SINGLE AGENTS FORMOTEROL FUMARATE AND BECLOMETHASONE DIPROPIONATE VIA pMDI WITH HFA-134A PROPELLANT, WHEN GIVEN AFTER INHALED ALLERGEN CHALLENGE IN ASTHMATIC PATIENTS - MART3
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Written informed consent
- •- Male and female outpatients, aged * 18 years and * 55 years
- •- Clinical diagnosis of atopic controlled asthma for at least 6 months, according to Global Strategy for Asthma Management and Prevention (GINA) revised version 2006 Guidelines, without severe exacerbation in the previous 6 months before study entry
- •- Patients only taking short-acting *2-agonists on an as needed basis
- •- A provocative concentration of methacoline chloride or histamine causing a 20% fall in FEV1 (PC20) < 8 mg/ml
- •- A positive skin prick test (SPT) for house dust mite
- •- A documented EAR (* 20% fall in FEV1 from baseline, 0-3 h post allergen) and a LAR (* 15% fall in FEV1 from baseline, 3-8 h post-allergen) following inhaled allergen extract
- •- A co-operative attitude and ability to correctly use the device
排除标准
- •- Current smokers or recent (less than one year) ex-smokers
- •- Evidence of severe asthma exacerbation in the previous 6 months
- •- Clinically significant history of upper/lower respiratory tract infection within 4 weeks from the start of the study
- •- Clinically significant or unstable concurrent disease : e.g. uncontrolled hyperthyroidism, uncontrolled diabetes mellitus or other endocrine disease; significant hepatic impairment; significant renal impairment; significant other pulmonary disease; cardiovascular disease; gastrointestinal disease; neurological disease; haematological disease, autoimmune disorders, laboratory and electrocardiographic abnormalities that may interfere with patient*s safety, compliance, or study evaluations, according to the investigator*s opinion
- •- Female subjects: pregnant or with active desire to be pregnant, lactating mother or lack of efficient contraception in a subject with child-bearing potential (i.e. contraceptive methods other than oral contraceptives, IUD, tubal ligature). A pregnancy test in urine is to be carried out in women of a fertile age at screening
- •- Patients treated with long-acting *2-agonists, anticholinergics and antihistamines and with topicalcorticosteroids and leukotriene antagonists during the previous 4 weeks
- •- Patients treated with beta-blockers in the week preceding the screening visit
- •- Patients who received systemic steroids in the previous 2 month
- •- Significant alcohol consumption or drug abuse
- •- Patients with allergy, sensitivity or intolerance to sympathomimetic drugs or corticosteroids or to any of the excipients contained in the study drugs
- •- Inability to perform spirometry of acceptable quality (according to ERS guidelines)or any other acute or chronic condition that put the patient at risk or may alter the interpretation of the test.
- •- Patients who received any investigational new drug or participated in clinical study within the previous 8 weeks before study entry
研究者
相似试验
进行中（未招募）
不适用
A DOUBLE BLIND, SINGLE DOSE, RANDOMIZED, 4-PERIOD CROSS-OVER, PLACEBO-CONTROLLED CLINICAL STUDY OF FIXED COMBINATION BECLOMETHASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE (CHF 1535) VERSUS SINGLE AGENTS FORMOTEROL FUMARATE AND BECLOMETHASONE DIPROPIONATE VIA pMDI WITH HFA-134A PROPELLANT, WHEN GIVEN AFTER INHALED ALLERGEN CHALLENGE IN ASTHMATIC PATIENTS - MART3astmaEUCTR2008-002844-40-NLeiden University Medical Center20
尚未招募
不适用
A comparative Bioavailability study of CCL in Healthy VolunteersCTRI/2020/07/026856Akay Natural Ingredients Pvt Ltd
已完成
1 期
Comparative bioequivalence study of a generic formulation of fingolimod capsule against the innovator fingolimod capsule in fasting healthy subjectsACTRN12615001055594Zenith Technology Corporation Limited24
已完成
不适用
Bioequivalence study for Rifapentine 150 mg TabletsCTRI/2022/04/042197Cipla Ltd India40
进行中（未招募）
不适用
A SINGLE-DOSE, RANDOMIZED, TWO-PERIOD, CROSSOVER STUDY TO ASSESS BIOEQUIVALENCE BETWEEN TWO IBUPROFEN 200 MG TABLET FORMULATIONS, IN HEALTHY ADULTS.PainEUCTR2013-001442-34-SEMcNeil AB